Could a multiple sclerosis drug tame lung cancer?

NCT ID NCT06424067

Recruiting now Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests fingolimod, a drug already used for multiple sclerosis, in 38 adults with advanced non-small cell or small cell lung cancer that worsened after chemo-immunotherapy. Participants take a 0.5 mg pill daily. The study first checks safety, then looks at whether tumors shrink or stop growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fingolimod (Gilenya)
What this could lead to: If it works, this could offer a new treatment option for advanced lung cancer patients who have run out of standard therapies.
What could go wrong: This is a small, early-phase trial with only 38 participants, so results may not apply broadly. Fingolimod is known to cause side effects like heart issues and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER SMALL CELL LUNG CANCER

Contacts and locations

Locations

Hollings Cancer Center at Medical University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.